Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | David Cunningham, Niall C. Tebbutt, Irina Davidenko, André M. Murad, Salah-Eddin Al-Batran, David H. Ilson, Sergei Tjulandin, Evgeny Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki Abdulaziz Tejani, Anghel Adrian Udrea et. al. | ||||||||||||
Title | Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/147255-156 | ||||||||||||
Abstract Text | J Clin Oncol 33, 2015 (suppl; abstr 4000) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|